DMPI - DelMar Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.6150
-0.0250 (-3.91%)
At close: 3:59PM EDT

0.6350 +0.02 (3.25%)
After hours: 5:58PM EDT

Stock chart is not supported by your current browser
Previous Close0.6400
Open0.6416
Bid0.6150 x 2200
Ask0.6266 x 900
Day's Range0.5900 - 0.6520
52 Week Range0.5520 - 8.5000
Volume337,919
Avg. Volume804,689
Market Cap7.004M
Beta (3Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-3.1570
Earnings DateSep 23, 2019 - Sep 27, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019
    PR Newswire

    DelMar Pharmaceuticals to Present at the Fall Investor Summit on September 16, 2019

    SAN DIEGO , Sept. 11, 2019 /PRNewswire/ --  DelMar Pharmaceuticals, Inc.  (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel ...

  • DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates
    PR Newswire

    DelMar Pharmaceuticals Announces Fiscal Year 2019 Financial Results and Recent Corporate Updates

    Company Estimates Cash Runway Sufficient to Report Top-Line Results from Two of Three Patient Groups in Phase 2 Trials By 4th Quarter of Calendar Year 2020 SAN DIEGO , Sept. 10, 2019 /PRNewswire/ -- DelMar ...

  • DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria
    PR Newswire

    DelMar Pharmaceuticals Reports Full Compliance with Nasdaq Listing Criteria

    SAN DIEGO , Sept. 9, 2019 /PRNewswire/ --  DelMar Pharmaceuticals, Inc.  (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel ...

  • DelMar Pharmaceuticals Relocates Headquarters to San Diego, California
    PR Newswire

    DelMar Pharmaceuticals Relocates Headquarters to San Diego, California

    SAN DIEGO , Sept. 4, 2019 /PRNewswire/ --  DelMar Pharmaceuticals, Inc.  (Nasdaq: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel ...

  • Benzinga

    The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 27) Castle Biosciences Inc (NASDAQ: CSTL ) The Medicines ...

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For August 27, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Taronis Technologies (NASDAQ: TRNX ) shares ...

  • DelMar Pharmaceuticals Anticipates Current Cash Runway Will Provide Sufficient Capital for Full Enrollment in All Three Patient Groups in Two Phase 2 Clinical Trials
    PR Newswire

    DelMar Pharmaceuticals Anticipates Current Cash Runway Will Provide Sufficient Capital for Full Enrollment in All Three Patient Groups in Two Phase 2 Clinical Trials

    VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 27, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announced that the Company anticipates that its current cash position, which includes the $6.7 million in net proceeds from the underwritten offering completed August 16, 2019, will be sufficient to complete enrollment in all three patient groups of its two ongoing Phase 2 clinical trials for its lead compound, VAL-083, which the Company believes will occur by the fourth quarter of calendar year 2020. The Company's Phase 2 trial in China is a single-arm, open-label study testing VAL-083 in combination with standard radiotherapy in GBM patients who have an unmethylated promoter of the methylguanine DNA-methyltransferase (MGMT) gene.  The clinical trial in newly-diagnosed GBM patients is designed to determine if first-line treatment with VAL-083 plus radiotherapy can provide improvements over the historical efficacy of standard of care temozolomide (TMZ) plus radiotherapy.  Efficacy will be measured based on tumor response to treatment, progression-free survival, progression-free survival at six months, and overall survival compared to historical results in the target population.  To date, the Company has enrolled 20 of the 30 patients required for the trial, with positive early results previously reported.

  • Benzinga

    The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 15) Novocure Ltd (NASDAQ: NVCR ) Down In The Dumps (Biotech ...

  • DelMar Pharmaceuticals Announces Pricing Of $6.8 Million Underwritten Public Offering
    PR Newswire

    DelMar Pharmaceuticals Announces Pricing Of $6.8 Million Underwritten Public Offering

    VANCOUVER, British Columbia and MENLO PARK, Calif. , Aug. 14, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) ("DelMar" or the "Company"), a biopharmaceutical company ...

  • DelMar Pharmaceuticals Reports Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 as First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)
    PR Newswire

    DelMar Pharmaceuticals Reports Updated Results on Twenty Patients from the Phase 2 Clinical Trial of VAL-083 as First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)

    As of August 1, 2019, 17 of the first 20 enrolled patients have received at least their first assessment (two patients have not been enrolled long enough to receive their first assessment and one patient died before their first assessment).

  • DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)
    PR Newswire

    DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)

    VANCOUVER, British Columbia and MENLO PARK, Calif., July 31, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announces it has achieved two-thirds enrollment in its ongoing Phase 2 clinical study investigating the first-line treatment of VAL-083 with radiation therapy in newly-diagnosed MGMT-unmethylated GBM. The trial, which is being conducted at the Sun Yat-sen University Cancer Center (SYSUCC) in Guangzhou, China and in collaboration with Guangxi Wuzhou Pharmaceutical Company, is designed to enroll up to 30 patients to determine whether first-line therapy with VAL-083 treatment improves progression free survival (PFS). The current standard of care is first-line temozolomide (TMZ) with radiation.

  • Benzinga

    Here Is What's Driving The Rally In DelMar Pharmaceuticals

    DelMar, which focuses on developing novel cancer therapies, said it has enrolled the first patient in the adjuvant trial arm of the Phase 2 study that is evaluating its VAL-083 in MGMT-unmethylated glioblastoma multiforme. GBM is an aggressive cancer that forms in the brain. The company said the recently-approved arm of the study will enroll up to 24 newly-diagnosed patients who have undergone surgery and chemoradiation with temozolomide, who will start receiving VAL-083 as an adjuvant therapy.

  • DelMar Pharmaceuticals Enrolls First Patient in the Recently-Approved Adjuvant Setting Arm of Phase 2 Study of VAL-083 for the Treatment of MGMT-Unmethylated Glioblastoma Multiforme
    PR Newswire

    DelMar Pharmaceuticals Enrolls First Patient in the Recently-Approved Adjuvant Setting Arm of Phase 2 Study of VAL-083 for the Treatment of MGMT-Unmethylated Glioblastoma Multiforme

    VANCOUVER, British Columbia and MENLO PARK, Calif., July 24, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, today announces that the first patient has been treated in the adjuvant (pre-temozolomide maintenance) trial arm of VAL-083's Phase 2 study in MGMT-unmethylated glioblastoma multiforme (GBM) being conducted at the University of Texas MD Anderson Cancer Center (MDACC).  This recently-approved arm of the study will enroll up to 24 newly-diagnosed patients who have undergone surgery and chemoradiation with temozolomide (TMZ) but will now receive VAL-083 in place of standard of care TMZ for adjuvant therapy.

  • DelMar Announces Relocation of Company Headquarters to San Diego
    PR Newswire

    DelMar Announces Relocation of Company Headquarters to San Diego

    VANCOUVER, British Columbia and MENLO PARK, Calif., July 10, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies, announced today that it has initiated the process of relocating the Company's headquarters from Vancouver, British Columbia to San Diego, CA.

  • Benzinga

    The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Down In The ...

  • Delmar Pharmaceuticals Announces Termination Of Rights Offering
    PR Newswire

    Delmar Pharmaceuticals Announces Termination Of Rights Offering

    VANCOUVER, British Columbia and MENLO PARK, Calif., June 27, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced it has terminated the rights offering of its securities previously announced on April 18, 2019. The termination results from an assessment by the Company's management that current market conditions are not conducive for an offering on terms that would be in the best interests of the Company's shareholders. The Company intends to withdraw its registration statement on Form S-1 and post-effective amendment thereto related to the rights offering previously filed with the US Securities and Exchange Commission.

  • DelMar Pharmaceuticals Announces Extension Of Rights Offering To July 12, 2019
    PR Newswire

    DelMar Pharmaceuticals Announces Extension Of Rights Offering To July 12, 2019

    VANCOUVER, British Columbia and MENLO PARK, Calif., June 25, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it has completed the rights offering period and will be extending the subscription period until 5:00 PM Eastern time on July 12, 2019, unless further extended by the Company. Under the rights offering, DelMar distributed one non-transferable subscription right for each share of common stock and each participating warrant held on the record date.

  • Delmar Pharmaceuticals Updates The Terms Of Previously Announced Rights Offering
    PR Newswire

    Delmar Pharmaceuticals Updates The Terms Of Previously Announced Rights Offering

    VANCOUVER, British Columbia and MENLO PARK, Calif., June 11, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it has adjusted certain pricing information and key dates for its previously announced rights offering.  The subscription period for the rights offering will now expire at 5:00 PM Eastern time on June 25, 2019, unless extended by the Company.

  • DelMar Pharmaceuticals Announces Closing of Financing
    PR Newswire

    DelMar Pharmaceuticals Announces Closing of Financing

    VANCOUVER, British Columbia and MENLO PARK, Calif., June 5, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced the closing of its previously announced registered direct offering of 1,170,000 shares of common stock and, in a concurrent private placement, warrants to purchase 760,500 shares of common stock at a combined purchase price of $3.10 per share and related warrant. The gross proceeds from the offering, prior to deducting offering expenses and placement agent fees and expenses payable by the Company, were $3.6 million.

  • DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting
    PR Newswire

    DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting

    VANCOUVER, British Columbia and MENLO PARK, Calif., June 3, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of novel cancer therapies presented clinical updates from the Company's ongoing first- and second-line trials in patients with MGMT-unmethylated glioblastoma multiforme (GBM) at a key opinion leader (KOL) forum focused on brain tumors and the role of VAL-083 to address the unmet medical need in GBM during the 2019 American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL. At the KOL forum, the Company provided an update on the ongoing Phase 1/2 clinical study investigating the front line treatment of VAL-083 with radiation therapy in newly diagnosed MGMT-unmethylated GBM. This trial is being conducted at the Sun Yat-sen University Cancer Center (SYSUCC) in Guangzhou, China in collaboration with Guangxi Wuzhou Pharmaceutical Company.

  • DelMar Pharmaceuticals Announces $3.6 Million Registered Direct Offering
    PR Newswire

    DelMar Pharmaceuticals Announces $3.6 Million Registered Direct Offering

    VANCOUVER, British Columbia and MENLO PARK, Calif., June 3, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it entered into securities purchase agreements with certain institutional investors in connection with a registered direct offering of an aggregate of 1,170,000 shares of common stock and, in a concurrent private placement, warrants to purchase 760,500 shares of common stock. The combined purchase price for one share of common stock and each warrant will be $3.10, for aggregate gross proceeds of $3.6 million.

  • DelMar Pharmaceuticals Updates Key Dates of Rights Offering
    PR Newswire

    DelMar Pharmaceuticals Updates Key Dates of Rights Offering

    VANCOUVER, British Columbia and MENLO PARK, Calif., May 29, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today provided an update to stockholders regarding the Company's rights offering and the key dates relative to the offering.   Stockholders or interested parties are advised to direct all questions and informational requests to the contacts listed below.

  • ACCESSWIRE

    DelMar Pharmaceuticals, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 23, 2019 / DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI ) will be discussing their earnings results in their 2019 Third Quarter Earnings to be held on May 23, 2019 at 4:30 ...

  • DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board
    PR Newswire

    DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board

    VANCOUVER, British Columbia and MENLO PARK, Calif., May 20, 2019 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" or the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today the appointments of three additional world-class neuro-oncologists to its Scientific Advisory Board (SAB).

  • DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial Results
    PR Newswire

    DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2019 Financial Results

    - Company will host a business update conference call on May 23, 2019 at 4:30 PM Eastern Time - VANCOUVER, British Columbia and MENLO PARK, Calif. , May 15, 2019 /PRNewswire/ --  DelMar Pharmaceuticals, ...